Huma Therapeutics Releases Results from COVID-19 Study

Huma Therapeutics announced results of a new study in collaboration with the Medical Research Council Epidemiology Unit at the University of Cambridge showing that participants using Huma's clinical trial platform had high, sustained levels of engagement in an observational, fully remote COVID-19 study.

The study, published in the Journal of Medical Internet Research, involved 62.61% (2524/4031) participants from the longitudinal Fenland study.

Read more about the study here.